Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis
Key facts
- Where
- Asyut, EgyptSee the site
- Phase
- Phase 4
Where in Egypt
- Assiut university HospitalsAsyut, EgyptContact: Ali A Ali, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT06209047
- Record updated
- 17 July 2025
- Original description
Randomized single-center trial evaluating whether bronchoscopic instillation of levofloxacin or gentamicin improves outcomes compared to a sham bronchoscopic procedure in adult ICU patients with non-cystic fibrosis bronchiectasis requiring invasive mechanical ventilation. The primary outcome is a ranked composite of in-hospital mortality and time to ventilator liberation. Safety and procedural adverse events are closely monitored.Read full original descriptionShow less
A Randomized Sham-Controlled Trial of Bronchoscopic Levofloxacin and Gentamicin Versus Sham in Mechanically Ventilated Bronchiectasis: Acute and 1-Year Outcomes
Randomized single-center trial evaluating whether bronchoscopic instillation of levofloxacin or gentamicin improves outcomes compared to a sham bronchoscopic procedure in adult ICU patients with non-cystic fibrosis bronchiectasis requiring invasive mechanical ventilation. The primary outcome is a ranked composite of in-hospital mortality and time to ventilator liberation. Safety and procedural adverse events are closely monitored.
Inclusion: patients with bronchiectasis confirmed by high-resolution CT chest(HRCT); patients with acute exacerbation of bronchiectasis who need antibiotic treatment at the hospital due to exacerbation; mechanically ventilated patients in the respiratory ICU; Age more than or equal to 18 years.
Exclusion: patients with active pulmonary tuberculosis; patients with allergic bronchopulmonary aspergillosis; age less than 18 years; patients who underwent interventional bronchoscopy for hemoptysis.